Gosset
Book a demo

AACR Annual Meeting 2026: key results and trends

What the 7,579 abstracts at AACR Annual Meeting 2026 reported, drug by drug: the readouts that stood out and the targets and modalities that dominated.

abstracts
7,579
drug-linked abstracts
2,852
companies
880
from Phase 3 studies
36

Drug-linked abstracts by phase

  • Phase 1 225
  • Phase 1/2 92
  • Phase 2 112
  • Phase 2/3 3
  • Phase 3 36

Key results

Quotes are taken verbatim from each abstract's results; selection is automated. Report an issue

  1. Phase 3Non-small cell lung cancer (NSCLC)Xuanzhu Biopharmaceutical

    dirozalkib

    Dirozalkib versus crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Results from the multicenter, randomized, open-label phase 3 trial

    The INV-assessed median PFS (mPFS) was significantly longer in the dirozalkib group than in the crizotinib group (29.50 mo [95%CI: 20.30-not reached] vs. 12.94 mo [11.07-17.61]; hazard ratio [HR] = 0.474, P < 0.0001).

    Read the abstract (opens in a new tab)

  2. Phase 3Non-small cell lung cancer (NSCLC)Merck

    pembrolizumab + ramucirumab

    Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

    In SCC, the HR (95% CI) was 0.90 [0.66-1.22] p= 0.25 with mOS of 10.7 mos for RP and 9.6 mos with SOC.

    Read the abstract (opens in a new tab)

  3. Phase 3Uveal melanoma (UM)

    tebentafusp

    Five-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase 3 trial

    With extended follow-up, the OS continued to favor tebentafusp, with a stratified hazard ratio of 0.67 (95% CI, 0.54-0.85).

    Read the abstract (opens in a new tab)

  4. Phase 2Biliary cancer

    durvalumab

    Enhanced monocyte activation and T cell cytotoxicity underlie the benefit of neoadjuvant durvalumab plus gemcitabine-cisplatin (D+GP) in localized biliary tract cancer (BTC): Phase 2 DEBATE study

    In the D+GP group, the objective response rate was 38.7%, median PFS 19 months (1-sided 80% CI, 15-21), and OS 28 months (24-43), versus 14.3%, 6 months (3-11), and 30 months (23-44) in the GP group.

    Read the abstract (opens in a new tab)

  5. Phase 1/2Non-small cell lung cancer (NSCLC)Hengrui Therapeutics

    trastuzumab rezetecan

    SHR-A1811 ± adebrelimab as first-line (1L) treatment for advanced HER2-mutant NSCLC: A randomized phase 2 cohort from a phase 1b/2 study

    PFS events occurred in 10 pts (27.8%) with combo vs 13 (40.6%) with SHR-A1811; median PFS was NR (95% CI 15.3-NR) vs 17.9 mo (95% CI 9.7-NR; HR 0.65, 95% CI 0.28-1.47).

    Read the abstract (opens in a new tab)

  6. Phase 1/2Hepatocellular carcinoma (HCC)

    muzastotug

    Results from the phase 1b/2 Morpheus liver study in patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC): Muzastotug (ADG126: masked anti-CTLA-4 Ab) combination arm

    Serious AEs occurred in 33% of cases for the ADG126 arm compared to 55% for control.

    Read the abstract (opens in a new tab)

  7. Phase 1/2Colorectal cancer (CRC)

    elisrasib

    Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study

    In combo CRC arm, 31/31 (100%) pts had any grade TRAEs, 15/31 (48.4%, including 19.4% related to elisrasib) pts had G3 TRAEs.

    Read the abstract (opens in a new tab)

  8. Phase 1/2Melanoma

    mRNA-4359

    First-Line mRNA-4359 plus pembrolizumab (pembro) in locally advanced or metastatic melanoma: Results from the phase 1/2 mRNA-4359-P101 study

    mRNA-4359-related TEAEs occurred in 11 pts (92%; all grade 1/2); the most common TEAE was injection site pain (67%).

    Read the abstract (opens in a new tab)

  9. Phase 1/2Neuroendocrine carcinoma (NEC)

    zocilurtatug pelitecan

    Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors

    One pt (3.6%) decreased the dose of ZL-1310 due to AE (G3 neutrophil count decreased); one pt (3.6%) experienced G2 interstitial lung disease leading to treatment discontinuation.

    Read the abstract (opens in a new tab)

  10. Phase 1/2Pancreatic cancer (PC)

    narmafotinib

    Narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial) a Phase 1b 2a study-Interim analysis

    Most common AEs related to narmafotinib were nausea (29%), diarrhea (16%), vomiting (15%), fatigue (11%), gastroesophageal reflux (7%) and constipation (6%), which were predominantly grade 1-2 in severity.

    Read the abstract (opens in a new tab)

  11. Phase 1/2Nonhematologic neoplasmsBicycle Therapeutics

    nuzefatide pevedotin

    An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with nivolumab in patients (pts) with advanced solid tumors: Results from a Phase 1/2 study

    The most common BT5528-related adverse events (TRAEs) were fatigue (29%), nausea (24%), diarrhea (19%), and vomiting (14%).

    Read the abstract (opens in a new tab)

  12. Phase 1/2Nonhematologic neoplasms

    D3S-002

    First in human phase 1 study of D3S-002, a purposely designed ERK1/2 inhibitor, in advanced solid tumors with MAPK pathway mutations

    D3S-002 was well tolerated, with ≥Grade 3 TRAEs observed in 18.8% (6/32) of patients.

    Read the abstract (opens in a new tab)

Small molecules were the most frequent modality (59% of drug-linked abstracts). PDCD1 was the most frequent target (4%). Breast cancer was the most frequent disease (12%).

What the abstracts covered

Share of the 2,852 drug-linked abstracts, by the target, modality, disease and company of each drug. An abstract can count in more than one row, so a list can add up to more than 100%.

  • Antibody-drug conjugates12%353 drug-linked abstracts
  • Bispecific antibodies8%239 drug-linked abstracts

Top targets

  1. PDCD11104%
  2. TUBB1064%
  3. EGFR1034%
  4. ERBB2993%
  5. CD3933%
  6. CD274712%
  7. TOP1642%
  8. HRAS411%
  9. CD19401%
  10. TACSTD2401%

Top modalities

  1. Small molecules1,69159%
  2. Antibody-drug conjugates35312%
  3. Monoclonal antibodies34312%
  4. Bispecific antibodies2398%
  5. Cell therapies1716%
  6. Non-antibody therapeutic proteins1024%
  7. Peptides963%
  8. Oligonucleotide and RNA therapeutics853%

Top diseases

  1. Breast cancer33112%
  2. Non-small cell lung cancer (NSCLC)31311%
  3. Colorectal cancer (CRC)30311%
  4. Triple-negative breast cancer (TNBC)1977%
  5. Pancreatic adenocarcinoma (PDAC)1867%
  6. Pancreatic cancer (PC)1776%
  7. Ovarian cancer1636%
  8. Glioblastoma (GBM)1445%
  9. Gastric cancer (GC)1385%
  10. Prostate cancer (PCa)1365%

Most active companies

  1. AstraZeneca973%
  2. Bristol Myers Squibb813%
  3. Merck642%
  4. Pfizer632%
  5. Novartis532%
  6. Genentech492%
  7. Daiichi Sankyo482%
  8. GSK482%
  9. Eli Lilly331%
  10. REVOLUTION Medicines321%

Explore every AACR 2026 result in Gosset

All 2,852 drug-linked abstracts, joined to each drug’s trials, targets, developers and deals, with a source behind every line.

This page shows a sample of results. Gosset has the abstracts from this meeting and 100+ others; reach out for full access.

Get full accessExplore the results in Gosset

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call